Valuation: Ocugen, Inc.

Market Cap 427M 370M 344M 317M 598M 40.72B 608M 4.07B 1.59B 20.22B 1.6B 1.57B 68.01B P/E 2026 *
-5.58x
P/E 2027 * -5.21x
Enterprise Value 364M 316M 294M 271M 510M 34.75B 519M 3.48B 1.36B 17.26B 1.37B 1.34B 58.05B EV / Sales 2026 *
83.4x
EV / Sales 2027 * 38.7x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+5.88%
1 week-0.79%
Current month-17.65%
1 month-17.65%
3 months-27.17%
6 months-13.10%
Current year-6.67%
1 week 1.17
Extreme 1.17
1.32
1 month 1.17
Extreme 1.17
1.6
Current year 1.16
Extreme 1.16
2.72
1 year 0.93
Extreme 0.931
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 2019-09-26
Director of Finance/CFO - 2026-02-08
Chief Operating Officer - 2026-02-28
Director TitleAgeSince
Chairman 62 2019-09-26
Director/Board Member 59 2013-08-31
Director/Board Member 59 2019-08-31
Date Insider Type Main position Quantity % Market Cap.
4/1/26 Fiscal year

Director

388,268 0.1184%
1/2/26 Free

Chief Executive Officer

6,246,402 2.0000%
1/2/26 Free

Controller/Auditor

518,250 0.1659%
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%-0.79%+17.76%+111.41% 403M
-0.80%+5.16%-0.70%+13.00% 48.95B
-3.95%+14.70%+24.15%+5.15% 40.75B
+6.22%+1.81%+419.17%+647.45% 38.46B
-1.57%-1.44%+7.38%+43.06% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-0.39%-0.63% - - 16.62B
-1.13%-4.54%+32.10%+126.95% 16.33B
-7.10%-2.81%-8.80%-34.35% 13.65B
-0.06%+3.75%+3.81%+10.08% 13.56B
Average +0.27%+4.68%+56.28%+108.25% 25.35B
Weighted average by Cap. +0.08%+7.18%+76.54%+129.01%

Financials

2026 *2027 *
Net sales 4.37M 3.79M 3.52M 3.25M 6.12M 417M 6.23M 41.7M 16.33M 207M 16.4M 16.04M 696M 11.02M 9.57M 8.89M 8.2M 15.44M 1.05B 15.72M 105M 41.2M 522M 41.38M 40.47M 1.76B
Net income -76.84M -66.75M -61.98M -57.16M -108M -7.34B -110M -734M -287M -3.64B -289M -282M -12.25B -85.3M -74.09M -68.8M -63.45M -120M -8.14B -122M -815M -319M -4.04B -320M -313M -13.6B
Net Debt -62.5M -54.29M -50.41M -46.49M -87.58M -5.97B -89.16M -597M -234M -2.96B -235M -230M -9.97B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
26-07-30 US$1.260 +5.88% 3,506,950
26-07-29 US$1.190 -4.03% 6,983,650
26-07-28 US$1.240 -1.59% 4,879,004
26-07-27 US$1.260 +4.13% 5,037,488
26-07-24 US$1.210 -4.72% 4,119,147
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.260USD
Average target price
11.43USD
Spread / Average Target
+807.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock